0.49
+0.0027(+0.56%)
Currency In USD
| Previous Close | 0.48 |
| Open | 0.47 |
| Day High | 0.53 |
| Day Low | 0.47 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 5.18M |
| Average Volume | 32.39M |
| Market Cap | 29.38M |
| PE | -0.35 |
| EPS | -1.39 |
| Moving Average 50 Days | 0.44 |
| Moving Average 200 Days | 0.84 |
| Change | 0 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.01 as of August 24, 2025 at a share price of $0.486. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $12.8 as of August 24, 2025 at a share price of $0.486.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire Inc.
Aug 18, 2025 11:30 AM GMT
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable sa
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
GlobeNewswire Inc.
Aug 15, 2025 11:30 AM GMT
HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syst
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
GlobeNewswire Inc.
Aug 14, 2025 11:30 AM GMT
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide® may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biol